Millipore Sigma Vibrant Logo
Attention: We have moved. Merck Millipore products are no longer available for purchase on MerckMillipore.com.Learn More

435930 LIM Kinase Inhibitor I, LIMKi 3 - Calbiochem

LIM Kinase Inhibitor I, LIMKi 3, CAS 1338247-35-0, is a cell-permeable, potent inhibitor of LIM kinase (IC50 = 7 & 8 nM against LIMK1 & LIMK2, respectively). Reduces MDA-MB-231 tumor cell invasion.

LIM Kinase Inhibitor I, LIMKi 3 - Calbiochem MSDS (material safety data sheet) or SDS, CoA and CoQ, dossiers, brochures and other available documents.

Synonyms: N-(5-(1-(2,6-Dichlorophenyl)-3-(difluoromethyl)-1H-pyrazol-5-yl)thiazol-2-yl)isobutyramide

Primary Target: LIMK1 and LIMK2
435930
Purchase on Sigma-Aldrich

Áttekintés

Replacement Information

Kulcsspecifikációk táblázata

CAS #Empirical Formula
1338247-35-0C₁₇H₁₄Cl₂F₂N₄OS

Products

KatalógusszámCsomagolás Menny./csomag
435930-10MG Üvegpalack 10 mg
Description
OverviewA cell-permeable pyrazolylthiazolo-isobutyramide compound that acts as a potent LIM kinase inhibitor (IC50 = 7 and 8 nM against LIMK1 and LIMK2, respectively) and effectively suppresses cellular cofilin phosphorylation (IC50 ~ 1 µM in A549 and MDA-MB-231 cultures) without affecting tubulin polymerization or inducing cytotoxicity (EC50 >10 µM in A549 proliferation & colony formation assays). Shown to effectively destabilize F-actin structure in MDA-MB-231 breast cancer cells (3 to 10 µM) with concomitant blockage of invasion (by 93% at 10 µM).
Catalogue Number435930
Brand Family Calbiochem®
SynonymsN-(5-(1-(2,6-Dichlorophenyl)-3-(difluoromethyl)-1H-pyrazol-5-yl)thiazol-2-yl)isobutyramide
References
ReferencesScott, R.W., et al. 2010. J. Cell. Biol. 191, 169.
Ross-Macdonald, P., et al. 2008. Mol. Cancer Ther. 7, 3490.
Product Information
CAS number1338247-35-0
FormBeige powder
Hill FormulaC₁₇H₁₄Cl₂F₂N₄OS
ReversibleY
Structure formula ImageStructure formula Image
Quality LevelMQ100
Applications
ApplicationLIM Kinase Inhibitor I, LIMKi 3, CAS 1338247-35-0, is a cell-permeable, potent inhibitor of LIM kinase (IC50 = 7 & 8 nM against LIMK1 & LIMK2, respectively). Reduces MDA-MB-231 tumor cell invasion.
Biological Information
Primary TargetLIMK1 and LIMK2
Primary Target IC<sub>50</sub>7 and 8 nM against LIMK1 and LIMK2, respectively
Secondary targetAMPKA1, AMPKA2, DDR1, PAK3, DCAMKL2
Purity≥95% by HPLC
Physicochemical Information
Cell permeableY
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Storage and Shipping Information
Ship Code Ambient Temperature Only
Toxicity Standard Handling
Storage +2°C to +8°C
Protect from Light Protect from light
Do not freeze Ok to freeze
Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
Packaging Information
Packaged under inert gas Packaged under inert gas
Transport Information
Supplemental Information
Specifications
Global Trade Item Number
Katalógusszám GTIN
435930-10MG 04055977210330

Documentation

LIM Kinase Inhibitor I, LIMKi 3 - Calbiochem MSDS

Title

Safety Data Sheet (SDS) 

LIM Kinase Inhibitor I, LIMKi 3 - Calbiochem Certificates of Analysis

TitleLot Number
435930

References

Hivatkozások áttekintése
Scott, R.W., et al. 2010. J. Cell. Biol. 191, 169.
Ross-Macdonald, P., et al. 2008. Mol. Cancer Ther. 7, 3490.
Data Sheet

Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

Revision22-November-2012 JSW
SynonymsN-(5-(1-(2,6-Dichlorophenyl)-3-(difluoromethyl)-1H-pyrazol-5-yl)thiazol-2-yl)isobutyramide
DescriptionA cell-permeable pyrazolylthiazolo-isobutyramide compound that acts as a potent LIM kinase inhibitor (IC50 = 7 and 8 nM against LIMK1 and LIMK2, respectively) and effectively suppresses cellular cofilin phosphorylation (IC50 ~ 1 µM in A549 and MDA-MB-231 cultures) without affecting tubulin polymerization or inducing cytotoxicity (EC50 >10 µM in A549 proliferation and colony formation assays). Shown to effectively destabilize F-actin structure in MDA-MB-231 breast cancer cells (3 to 10 µM) with concomitant blockage of invadopedia-mediated ECM degradation (13% and 10% of control, respectively, by 3 and 10 µM inhibitor) and invasion (45% and 7% of control invasion rate, respectively, by 3 and 10 µM inhibitor). Although reported to exhibit affinity toward AMPKα1 and AMPKα2 in T7 phage-based competition binding studies, inhibitory activity of LIMKi 3 against AMPKα1/2 is not yet directly demonstrated.
FormBeige powder
Intert gas (Yes/No) Packaged under inert gas
CAS number1338247-35-0
Structure formulaStructure formula
Purity≥95% by HPLC
SolubilityDMSO (100 mg/ml)
Storage Protect from light
+2°C to +8°C
Do Not Freeze Ok to freeze
Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
Toxicity Standard Handling
ReferencesScott, R.W., et al. 2010. J. Cell. Biol. 191, 169.
Ross-Macdonald, P., et al. 2008. Mol. Cancer Ther. 7, 3490.